Abstract 1853P
Background
Frankl's Logotherapy is a psychotherapeutic approach aimed at finding meaning in life. Although the incidence of death anxiety, existential loneliness, and depression in cancer patients is high, the efficacy of Logotherapy in this population is not well established.
Methods
Two independent investigators searched PubMed, Embase, and Cochrane Library databases up to March 2023. We systematically reviewed, according to PRISMA guidelines, controlled clinical trials evaluating the use of Logotherapy in cancer anxiety symptoms. We performed a pooled analysis on anxiety scores of patients that underwent group Logotherapy sessions vs. non-exposed control groups.
Results
We included seven studies, four randomized controlled trials (RCTs), and three quasi-experimental, comprising 280 patients, published between 1977 and 2023. A total of 139 patients (49.6%) had sessions of Logotherapy, and ages ranged from 18 to more than 68 years. Total treatment duration ranged between 360 and 1200 minutes. The Standard Mean Difference (SMD) for anxiety symptoms was -1.63 (95% CI = [-2.65, -0.61]; z = 3.12; P = 0.002; I2 = 92%) in patients who underwent Logotherapy compared to non-exposed control groups. In a subgroup analysis including only RCTs, a similar effect was observed with an SMD of -0.64 (95% CI = [-1.72, 0.44]; z = 1.16; P = 0.25; I2 = 91%).
Conclusions
Despite limited evidence, Logotherapy group sessions were associated with a reduction in anxiety scores of adult patients with cancer when compared to inactive control groups.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
A.V. Teixeira Filho.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1604P - A comparative study of symptom prevalence between adults and elderly patients with advanced cancer diagnosis under palliative care: A single institution experience
Presenter: Hodan Abdullah
Session: Poster session 05
1605P - The impact of cancer pain on survival of lung cancer patients receiving immune checkpoint inhibitors
Presenter: Sichao Wang
Session: Poster session 05
1606P - Sarcopenia, depression, and modes of feeding among cancer patients
Presenter: Muhammad Khokhar
Session: Poster session 05
1607P - Patient perceptions of the efficacy, safety, and quality of the evidence available on medicinal cannabis: A survey of Australian cancer patients - comparing users to non-users
Presenter: Joseph Taylor
Session: Poster session 05
1608P - Albumin-myosteatosis gauge as a prognostic factor in patients with advanced pancreatic cancer undergoing first-line chemotherapy
Presenter: Omer Dizdar
Session: Poster session 05
1609P - A machine learning-based prognostic model to predict survival in patients with advanced cancer admitted to an acute palliative care unit
Presenter: Eun Hee Jung
Session: Poster session 05
1610P - A new updated prognostic index for patients with brain metastases (BM) treated with palliative whole brain radiotherapy (WBRT) in the era of precision oncology: METASNCore project
Presenter: Pablo Flores Paco
Session: Poster session 05
1611P - Family carers’ experiences with brain metastases: A longitudinal qualitative study
Presenter: Tonje Lundeby
Session: Poster session 05
1612P - Demonstrating the complexity of need and the effectiveness of integrated palliative care: An analysis of routinely collected patient centred outcome measures
Presenter: Joanne Hayes
Session: Poster session 05
1613P - The BreakThrough cancer malnutrition
Presenter: Stefano De Santis
Session: Poster session 05